Frankfurt
18.12.25 | 15:29
3,640 Euro
-2,15 % -0,080
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | INVENTIVA: Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference | 213 | GlobeNewswire (Europe) | Daix) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH")... ► Artikel lesen | |
| 28.11. | Inventiva S.A. - 6-K, Report of foreign issuer | 13 | SEC Filings | ||
| 28.11. | INVENTIVA: Results of the Votes of the Combined Shareholders' General Meeting of November 27, 2025 | 579 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 28, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 24.11. | INVENTIVA: Information relating to the stabilization activities carried out in the context of its recent offering | 332 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 24, 2025 - Publication of information relating to the stabilization activities carried out in the context of the recent public offering... ► Artikel lesen | |
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 24.11. | Inventiva S.A. reports nine-months results | 4 | Seeking Alpha | ||
| 21.11. | Inventiva S.A reports 9M results | 1 | Seeking Alpha | ||
| 21.11. | INVENTIVA: Inventiva reports 2025 Third Quarter Financial Information | 774 | GlobeNewswire (Europe) | Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine months of 2025.Cash runway expected until the... ► Artikel lesen | |
| 18.11. | Inventiva stock price target lowered to $11 at Guggenheim on financing | 4 | Investing.com | ||
| 17.11. | INVENTIVA: Inventiva announces full exercise of Underwriters' Option, bringing proceeds of Offering to approximately $172.5M | 372 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 17, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 13.11. | Inventiva S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.11. | Inventiva Prices Of Upsized Public Offering Of About $150 Mln ADS | 1 | RTTNews | ||
| 13.11. | Inventiva resumes trading on Euronext Paris after ADS offering halt | 1 | Investing.com | ||
| 13.11. | Inventiva: Handel an Euronext Paris nach Aussetzung wegen ADS-Angebots wieder aufgenommen | 2 | Investing.com Deutsch | ||
| 13.11. | INVENTIVA: Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares | 338 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 13, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 12.11. | INVENTIVA: Inventiva announces launch of public offering | 882 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 12, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 06.11. | INVENTIVA: Statement of total voting rights and shares forming the company's share capital as October 20, 2025 | 293 | GlobeNewswire (Europe) | Article R. 22-10-23 of the French Commercial Code Market: Euronext ParisISIN code / Mnemo: FR0013233012 / IVAWeb site: www.inventivapharma.com
Date Number of Shares Outstanding
... ► Artikel lesen | |
| 06.11. | INVENTIVA: Combined General Meeting of November 27, 2025 - Availability of the preparatory documents | 370 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 6, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 06.11. | Inventiva S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.10. | Inventiva S.A. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 14.10. | Inventiva S.A. - 6-K, Report of foreign issuer | 19 | SEC Filings |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 14,645 | +0,58 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| EDWARDS LIFESCIENCES | 72,91 | +0,77 % | Edwards Lifesciences upgraded at JP Morgan on TAVR, TMTT strength | ||
| HAPPY BELLY FOOD GROUP | 1,420 | +3,65 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Heal Wellness Signs A 10 Unit Development Agreement for the State of Colorado, USA | Toronto, Ontario--(Newsfile Corp. - December 17, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 141,20 | -0,25 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Upcoming Investor Events | DUBLIN, Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events:
Zanidatamab HERIZON-GEA-01... ► Artikel lesen | |
| DAIICHI SANKYO | 18,590 | +0,27 % | Astrazeneca und Daiichi Sankyo erhalten erweitere US-Zulassung für Enhertu | DJ Astrazeneca und Daiichi Sankyo erhalten erweitere US-Zulassung für Enhertu
Von Adria Calatayud
DOW JONES--Astrazeneca und Daiichi Sankyo haben in den USA die Zulassung für eine erweiterte... ► Artikel lesen | |
| AYTU BIOPHARMA | 1,570 | -100,00 % | Aytu BioPharma, Inc.: Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City | DENVER, CO / ACCESS Newswire / December 18, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 35,600 | -0,56 % | Rigel Pharmaceuticals, Inc.: Rigel Announces Publication of Final 5-year Data on REZLIDHIA (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology | Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously... ► Artikel lesen | |
| AUSCANN | - | - | Argent BioPharma Signs $15m Deal to Acquire Key Clinical and IP Assets from AusCann | ||
| TUHURA BIOSCIENCES | 0,780 | +3,31 % | TuHURA to release shares to Kintara CVR holders as trial meets endpoint | ||
| NRX PHARMACEUTICALS | 2,200 | +17,02 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion | Remaining $5.4 million debt was repaid through strategic equity conversion in common stock with no additional warrants or adjustment provisionsCompany anticipates that Dec 31 balance sheet will reflect... ► Artikel lesen | |
| CGN MINING | 0,320 | +0,63 % | Dividendenbekanntmachungen (23.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AECON GROUP INC CA00762V1094 0,19 CAD 0,12 EUR ARROWMARK FINANCIAL CORP US8617801043 0,45 USD 0,3905 EUR ASSECO POLAND SA PLSOFTB00016 3... ► Artikel lesen | |
| CHINA SHINEWAY PHARMACEUTICAL GROUP | 0,920 | 0,00 % | Dividendenbekanntmachungen (09.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALUMINUM CORPORATION OF CHINA LTD CNE1000001T8 0,1348 HKD 0,0147 EUR AMEREN CORPORATION US0236081024 0,71 USD 0,6037 EUR ANHUI... ► Artikel lesen | |
| FUTURA MEDICAL | 0,010 | +11,76 % | WT Lamb Investments reduces stake in Futura Medical to 2.25% | ||
| BENCHMARK HOLDINGS | 0,256 | -100,00 % | XFRA 31B: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBENCHMARK HLDGS... ► Artikel lesen | |
| BAYER | 35,300 | +0,56 % | Buy or Goodbye?: Bayer, LVMH, Carl Zeiss Meditec und Zalando - Analystenstimmen des Tages | © Foto: Thomas Banneyer/dpaBayer, LVMH, Carl Zeiss Meditec und Zalando: Die wichtigsten Analysten-Updates im Überblick.Berenberg hebt das Kursziel für Bayer an Die Privatbank Berenberg hat das Kursziel... ► Artikel lesen |
Das Unternehmen INVENTIVA SA ADR kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 3,640 Euro und damit -2,15 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.